| NCT07155174 | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2025-12-06 | 2031-09 | 2031-09 |
| NCT07196644 | A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | NOT_YET_RECRUITING | PHASE2 | 2025-11-25 | 2030-12 | 2030-12 |
| NCT07155187 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2025-11-15 | 2031-08 | 2031-08 |
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2025-11-12 | 2042-01 | 2042-01 |
| NCT07207369 | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars | NOT_YET_RECRUITING | PHASE3 | 2025-10-16 | 2029-11 | 2029-11 |
| NCT06953934 | A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants | NOT_YET_RECRUITING | PHASE1 | 2025-10-14 | 2026-02 | 2026-02 |
| NCT07186595 | A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance | NOT_YET_RECRUITING | PHASE4 | 2025-09-23 | 2026-08 | 2026-08 |
| NCT07007065 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | PHASE3 | 2025-09-17 | 2033-03 | 2033-03 |
| NCT05316220 | A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis | WITHDRAWN | PHASE3 | 2025-09-15 | 2026-07-19 | 2026-07-19 |
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer | NOT_YET_RECRUITING | PHASE2 | 2025-09-08 | 2029-01 | 2029-01 |
| NCT07141199 | A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers | RECRUITING | PHASE1 | 2025-09-02 | 2026-04 | 2026-04 |
| NCT06977724 | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) | RECRUITING | PHASE1 | 2025-08-26 | 2029-03 | 2029-03 |
| NCT07024797 | Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants | RECRUITING | PHASE1 | 2025-08-21 | 2026-03 | 2026-03 |
| NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | NOT_YET_RECRUITING | PHASE2 | 2025-08-20 | 2029-10 | 2029-10 |
| NCT07136103 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants | RECRUITING | PHASE1 | 2025-08-19 | 2026-05 | 2026-05 |
| NCT07160179 | Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | RECRUITING | PHASE1, PHASE2 | 2025-08-13 | 2029-10 | 2029-10 |
| NCT07023289 | A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | RECRUITING | PHASE2 | 2025-08-07 | 2029-11 | 2029-11 |
| NCT06896916 | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | RECRUITING | PHASE1 | 2025-08-07 | 2036-03 | 2036-03 |
| NCT07145918 | A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia | RECRUITING | PHASE2 | 2025-08-04 | 2028-02 | 2028-02 |
| NCT07005102 | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | RECRUITING | PHASE2, PHASE3 | 2025-08-03 | 2031-12 | 2031-12 |
| NCT07024784 | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | RECRUITING | PHASE2 | 2025-07-30 | 2028-02 | 2028-01 |
| NCT07071519 | A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis | RECRUITING | PHASE3 | 2025-07-28 | 2034-07 | 2034-07 |
| NCT07044687 | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | RECRUITING | PHASE4 | 2025-07-24 | 2027-11 | 2027-11 |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | RECRUITING | PHASE1, PHASE2 | 2025-07-23 | 2030-12 | 2030-12 |
| NCT07122583 | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System | RECRUITING | PHASE4 | 2025-07-22 | 2026-08 | 2026-08 |
| NCT07071532 | A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-07-15 | 2025-11 | 2025-11 |
| NCT06892522 | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | RECRUITING | PHASE1, PHASE2 | 2025-06-30 | 2036-03 | 2036-02 |
| NCT06972446 | A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | RECRUITING | PHASE2 | 2025-06-20 | 2027-11 | 2027-02 |
| NCT07023302 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata | RECRUITING | PHASE3 | 2025-06-19 | 2029-02 | 2029-02 |
| NCT06880744 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | RECRUITING | PHASE3 | 2025-06-17 | 2028-09 | 2028-09 |
| NCT07007091 | A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-06-12 | 2025-12 | 2025-11 |
| NCT06902558 | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | PHASE2 | 2025-06-09 | 2029-08 | 2029-08 |
| NCT06682988 | A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine | RECRUITING | PHASE2 | 2025-05-28 | 2028-03 | 2028-03 |
| NCT07032597 | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | ACTIVE_NOT_RECRUITING | PHASE3 | 2025-05-26 | 2026-10 | 2026-08 |
| NCT06696755 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | NOT_YET_RECRUITING | PHASE2 | 2025-05-15 | 2026-10-29 | 2026-10-29 |
| NCT06946524 | A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-05-08 | 2026-01 | 2026-01 |
| NCT06846320 | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | RECRUITING | PHASE2 | 2025-04-29 | 2026-11 | 2026-11 |
| NCT06820463 | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | RECRUITING | PHASE2 | 2025-04-24 | 2028-04 | 2028-03 |
| NCT06937619 | A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-04-21 | 2025-11 | 2025-11 |
| NCT06858813 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | RECRUITING | PHASE1 | 2025-04-14 | 2030-09 | 2030-09 |
| NCT06865105 | Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | RECRUITING | PHASE2 | 2025-04-11 | 2028-01 | 2028-01 |
| NCT06895343 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of ABBV-701 in Healthy Adult Western and Asian Participants | RECRUITING | PHASE1 | 2025-04-03 | 2026-10 | 2026-10 |
| NCT06895356 | A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants | COMPLETED | PHASE1 | 2025-03-26 | 2025-06-16 | 2025-06-16 |
| NCT06887010 | A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants | COMPLETED | PHASE1 | 2025-03-25 | 2025-09-16 | 2025-09-16 |
| NCT06772623 | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | RECRUITING | PHASE1, PHASE2 | 2025-03-06 | 2027-11 | 2027-11 |
| NCT06849791 | A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-02-26 | 2025-12 | 2025-11 |
| NCT06834789 | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-02-18 | 2025-12 | 2025-12 |
| NCT06810505 | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | RECRUITING | PHASE3 | 2025-02-13 | 2031-03 | 2031-03 |
| NCT06822738 | A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma | RECRUITING | PHASE3 | 2025-02-11 | 2028-11 | 2028-11 |
| NCT06806293 | Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | RECRUITING | PHASE3 | 2025-02-10 | 2027-07 | 2027-02 |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-01-27 | 2029-07 | 2029-07 |
| NCT06794866 | A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants | ACTIVE_NOT_RECRUITING | PHASE3 | 2025-01-22 | 2026-04 | 2026-04 |
| NCT06774313 | A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants | RECRUITING | PHASE1 | 2025-01-22 | 2025-12 | 2025-12 |
| NCT06568939 | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | PHASE2 | 2025-01-20 | 2028-02 | 2028-02 |
| NCT06632951 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) | ACTIVE_NOT_RECRUITING | PHASE2 | 2025-01-20 | 2028-08 | 2027-03 |
| NCT06667687 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | RECRUITING | PHASE1 | 2025-01-16 | 2031-11 | 2031-11 |
| NCT06783621 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products | RECRUITING | PHASE4 | 2025-01-16 | 2026-07 | 2026-07 |
| NCT06701331 | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | RECRUITING | PHASE3 | 2024-12-22 | 2027-01 | 2027-01 |
| NCT06718101 | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | RECRUITING | PHASE2 | 2024-12-19 | 2027-05 | 2027-05 |
| NCT06742086 | A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants | RECRUITING | PHASE1 | 2024-12-19 | 2025-09 | 2025-09 |
| NCT06734351 | A Study to Assess Safety and Effectiveness of Injections of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Change of Mid-Face Volume | RECRUITING | PHASE3 | 2024-12-16 | 2029-07 | 2029-07 |
| NCT06628310 | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | RECRUITING | PHASE2 | 2024-12-13 | 2030-10 | 2030-10 |
| NCT06078202 | A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers | WITHDRAWN | PHASE1 | 2024-12-01 | 2025-01-31 | 2025-01-31 |
| NCT06722417 | A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants | COMPLETED | PHASE1 | 2024-11-26 | 2025-01-17 | 2025-01-17 |
| NCT06722430 | A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants | COMPLETED | PHASE1 | 2024-11-13 | 2025-01-13 | 2025-01-13 |
| NCT06698926 | A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants | RECRUITING | PHASE1 | 2024-11-11 | 2025-12 | 2025-12 |
| NCT06614192 | A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | RECRUITING | PHASE3 | 2024-11-08 | 2028-10 | 2028-10 |
| NCT06575192 | Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants | RECRUITING | PHASE3 | 2024-11-05 | 2029-12 | 2029-12 |
| NCT06673238 | A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants | RECRUITING | PHASE1 | 2024-10-29 | 2026-04 | 2026-04 |
| NCT06618118 | A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder | TERMINATED | PHASE1 | 2024-10-23 | 2025-09-23 | 2025-09-23 |
| NCT06605599 | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder | RECRUITING | PHASE2 | 2024-10-15 | 2026-02 | 2026-01 |
| NCT06632938 | A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers | COMPLETED | PHASE1 | 2024-10-08 | 2025-05-15 | 2025-05-15 |
| NCT06602479 | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-10-07 | 2025-09-15 | 2025-09-15 |
| NCT06464692 | Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer | RECRUITING | PHASE1, PHASE2 | 2024-09-30 | 2028-09 | 2028-09 |
| NCT06571266 | A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants | COMPLETED | PHASE1 | 2024-09-11 | 2025-04-16 | 2025-04-16 |
| NCT06487559 | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) | RECRUITING | PHASE1 | 2024-09-11 | 2027-10 | 2027-10 |
| NCT06417775 | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | RECRUITING | PHASE3 | 2024-09-10 | 2027-09 | 2027-06 |
| NCT06579300 | A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 | SUSPENDED | PHASE1 | 2024-09-04 | 2026-08 | 2026-08 |
| NCT06548542 | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease | RECRUITING | PHASE2 | 2024-09-04 | 2028-08 | 2027-12 |
| NCT06300580 | Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers | COMPLETED | PHASE1 | 2024-08-21 | 2025-05-26 | 2025-05-26 |
| NCT06461897 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | RECRUITING | PHASE3 | 2024-08-19 | 2030-07 | 2030-07 |
| NCT06524635 | A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | RECRUITING | PHASE2 | 2024-08-14 | 2027-02 | 2027-02 |
| NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | RECRUITING | PHASE3 | 2024-08-05 | 2028-03 | 2028-03 |
| NCT06365853 | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | RECRUITING | PHASE2 | 2024-07-29 | 2027-06 | 2026-06 |
| NCT06332534 | Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease | RECRUITING | PHASE3 | 2024-07-26 | 2034-12 | 2027-06 |
| NCT06487572 | A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants | COMPLETED | PHASE1 | 2024-07-23 | 2025-02-07 | 2025-02-07 |
| NCT06547125 | A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2024-07-18 | 2026-02 | 2026-02 |
| NCT06477926 | A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants | COMPLETED | PHASE1 | 2024-07-09 | 2024-09-20 | 2024-09-20 |
| NCT06100744 | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | RECRUITING | PHASE3 | 2024-07-08 | 2028-10 | 2026-09 |
| NCT06468228 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | RECRUITING | PHASE3 | 2024-06-27 | 2026-12 | 2026-12 |
| NCT06402513 | A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe | COMPLETED | PHASE1 | 2024-06-24 | 2024-10-08 | 2024-10-08 |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | RECRUITING | PHASE1 | 2024-06-17 | 2027-02 | 2027-02 |
| NCT06389136 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | RECRUITING | PHASE3 | 2024-06-12 | 2027-03 | 2026-08 |
| NCT06093503 | Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein | WITHDRAWN | PHASE3 | 2024-05-31 | 2028-04-11 | 2028-04-11 |
| NCT06390722 | A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis | WITHDRAWN | PHASE3 | 2024-05-23 | 2026-07-08 | 2026-01-05 |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | RECRUITING | PHASE3 | 2024-05-19 | 2027-12 | 2027-12 |
| NCT06414798 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. | COMPLETED | PHASE1 | 2024-05-13 | 2025-02-08 | 2025-02-08 |
| NCT06333860 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | ACTIVE_NOT_RECRUITING | PHASE4 | 2024-05-10 | 2026-03 | 2025-12 |
| NCT06406348 | A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants | COMPLETED | PHASE1 | 2024-05-09 | 2025-04-22 | 2025-04-22 |
| NCT05606757 | A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique | WITHDRAWN | PHASE2 | 2024-05-07 | 2025-09-26 | 2025-04-22 |
| NCT06399718 | A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-04-30 | 2025-11 | 2025-11 |
| NCT06345339 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | RECRUITING | PHASE2, PHASE3 | 2024-04-26 | 2028-06 | 2027-09 |
| NCT06346288 | A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease | ACTIVE_NOT_RECRUITING | PHASE4 | 2024-04-24 | 2026-02-06 | 2025-10-01 |
| NCT06387394 | A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-04-22 | 2025-11 | 2025-11 |
| NCT06236438 | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | PHASE2, PHASE3 | 2024-04-10 | 2031-10 | 2031-10 |
| NCT06158854 | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion | RECRUITING | PHASE1, PHASE2 | 2024-04-01 | 2028-02 | 2025-12 |
| NCT06308198 | A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines | COMPLETED | PHASE3 | 2024-03-29 | 2025-02-26 | 2025-02-26 |
| NCT06241313 | Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine | RECRUITING | PHASE3 | 2024-03-25 | 2026-11 | 2025-07-07 |
| NCT06257875 | A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-03-23 | 2027-09 | 2027-09 |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | RECRUITING | PHASE1 | 2024-03-08 | 2027-05 | 2027-05 |
| NCT06278766 | A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration | COMPLETED | PHASE1 | 2024-02-21 | 2024-04-19 | 2024-04-19 |
| NCT06158958 | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-02-06 | 2028-01 | 2028-01 |
| NCT06218251 | A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines | COMPLETED | PHASE4 | 2024-02-05 | 2024-12-17 | 2024-07-25 |
| NCT06148181 | A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants | COMPLETED | PHASE1 | 2024-01-29 | 2024-12-30 | 2024-12-30 |
| NCT05956509 | Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity | TERMINATED | PHASE1 | 2024-01-12 | 2024-06-02 | 2024-06-02 |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | RECRUITING | PHASE2, PHASE3 | 2024-01-11 | 2030-09 | 2030-09 |
| NCT06151561 | Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines | COMPLETED | PHASE1 | 2024-01-05 | 2024-04-03 | 2024-04-03 |
| NCT06118411 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-19 | 2028-02 | 2025-10 |
| NCT06151535 | A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants | COMPLETED | PHASE2 | 2023-12-19 | 2025-02-24 | 2025-02-24 |
| NCT06174688 | A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants | COMPLETED | PHASE3 | 2023-12-12 | 2024-09-13 | 2024-09-13 |
| NCT05995353 | A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease | RECRUITING | PHASE3 | 2023-12-11 | 2029-04 | 2029-04 |
| NCT05821855 | A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China | RECRUITING | PHASE4 | 2023-12-08 | 2030-07 | 2030-07 |
| NCT06144684 | A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295 | RECRUITING | PHASE1 | 2023-11-29 | 2026-04 | 2026-04 |
| NCT06137287 | A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants | COMPLETED | PHASE3 | 2023-11-22 | 2025-07-31 | 2025-07-31 |
| NCT05995340 | ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-21 | 2026-08 | 2026-08 |
| NCT06054425 | A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults | COMPLETED | PHASE1 | 2023-11-20 | 2024-05-06 | 2024-05-06 |
| NCT06063967 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-15 | 2027-03 | 2027-03 |
| NCT06068868 | Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | TERMINATED | PHASE1 | 2023-11-13 | 2025-02-25 | 2025-02-25 |
| NCT06107413 | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | RECRUITING | PHASE2 | 2023-11-12 | 2026-10 | 2026-10 |
| NCT06084481 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | RECRUITING | PHASE1 | 2023-11-09 | 2026-07 | 2026-07 |
| NCT05782907 | Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. | RECRUITING | PHASE3 | 2023-11-06 | 2033-10 | 2028-08 |
| NCT06068855 | A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-10-17 | 2025-11 | 2025-11 |
| NCT06032546 | A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 | COMPLETED | PHASE2 | 2023-10-12 | 2025-09-22 | 2025-09-22 |
| NCT06012240 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata | RECRUITING | PHASE3 | 2023-10-11 | 2028-01 | 2028-01 |
| NCT05748483 | Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-10-07 | 2026-05 | 2025-04-28 |
| NCT06070948 | A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants | WITHDRAWN | PHASE1 | 2023-10-05 | 2025-07-28 | 2025-07-28 |
| NCT05609630 | Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. | RECRUITING | PHASE3 | 2023-10-02 | 2029-06 | 2029-06 |
| NCT06067568 | Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants | COMPLETED | PHASE1 | 2023-09-28 | 2024-02-26 | 2024-02-26 |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-09-21 | 2026-11 | 2026-11 |
| NCT06018987 | A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds | COMPLETED | PHASE2, PHASE3 | 2023-09-05 | 2025-02-03 | 2025-02-03 |
| NCT06024239 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) | COMPLETED | PHASE1 | 2023-08-31 | 2025-03-04 | 2025-03-04 |
| NCT06009237 | A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants | TERMINATED | PHASE1 | 2023-08-23 | 2023-10-30 | 2023-10-30 |
| NCT05995366 | A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration | COMPLETED | PHASE1 | 2023-08-18 | 2023-10-13 | 2023-10-13 |
| NCT05969223 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | ACTIVE_NOT_RECRUITING | PHASE4 | 2023-08-10 | 2025-11 | 2025-01-22 |
| NCT05941442 | A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | COMPLETED | PHASE2 | 2023-07-31 | 2025-03-31 | 2025-03-31 |
| NCT05940402 | A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function | COMPLETED | PHASE1 | 2023-07-24 | 2024-12-19 | 2024-12-19 |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | RECRUITING | PHASE3 | 2023-07-19 | 2027-10 | 2026-12 |
| NCT05861427 | Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine | COMPLETED | PHASE3 | 2023-07-12 | 2025-03-01 | 2025-03-01 |
| NCT05892757 | Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers | COMPLETED | PHASE1 | 2023-07-11 | 2024-02-22 | 2024-02-22 |
| NCT05935033 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | COMPLETED | PHASE1 | 2023-06-30 | 2025-02-21 | 2025-02-21 |
| NCT05878067 | A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants | COMPLETED | PHASE3 | 2023-06-27 | 2023-10-06 | 2023-10-06 |
| NCT05895266 | A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers | COMPLETED | PHASE1 | 2023-06-23 | 2023-11-02 | 2023-11-02 |
| NCT05889182 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | RECRUITING | PHASE3 | 2023-06-21 | 2028-03 | 2028-03 |
| NCT05814627 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-06-15 | 2026-08 | 2025-08 |
| NCT05909553 | Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers | COMPLETED | PHASE1 | 2023-06-15 | 2023-09-22 | 2023-09-22 |
| NCT05818709 | A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-06-14 | 2025-11 | 2025-11 |
| NCT05753501 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | RECRUITING | PHASE1 | 2023-06-09 | 2031-03 | 2031-03 |
| NCT05707949 | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine | ENROLLING_BY_INVITATION | PHASE3 | 2023-06-05 | 2032-04 | 2032-04 |
| NCT05507580 | A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE4 | 2023-05-29 | 2024-08-15 | 2024-07-11 |
| NCT05711394 | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | RECRUITING | PHASE3 | 2023-05-01 | 2028-05 | 2028-03 |
| NCT05760313 | A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | COMPLETED | PHASE2 | 2023-04-27 | 2025-06-09 | 2025-06-09 |
| NCT05771428 | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease | COMPLETED | PHASE2 | 2023-04-27 | 2024-09-12 | 2024-08-06 |
| NCT05512390 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | RECRUITING | PHASE1 | 2023-04-26 | 2027-02 | 2027-02 |
| NCT05785715 | Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis | TERMINATED | PHASE2 | 2023-04-24 | 2025-05-30 | 2025-05-30 |
| NCT05836506 | A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants | COMPLETED | PHASE1 | 2023-04-18 | 2023-06-20 | 2023-06-20 |
| NCT05741034 | A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants | COMPLETED | PHASE3 | 2023-04-07 | 2024-12-09 | 2024-12-09 |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | RECRUITING | PHASE1 | 2023-04-04 | 2027-06 | 2027-06 |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | RECRUITING | PHASE1 | 2023-03-21 | 2027-03 | 2027-03 |
| NCT05570006 | Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | COMPLETED | PHASE2 | 2023-03-16 | 2024-12-23 | 2024-12-23 |
| NCT05757141 | An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease | RECRUITING | PHASE1, PHASE2 | 2023-03-13 | 2029-11 | 2027-11 |
| NCT05738850 | Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants | COMPLETED | PHASE1 | 2023-02-15 | 2024-05-31 | 2024-05-31 |
| NCT05686980 | A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants | COMPLETED | PHASE1 | 2023-01-17 | 2023-03-30 | 2023-03-30 |
| NCT05527184 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | RECRUITING | PHASE1 | 2023-01-11 | 2027-02 | 2027-02 |
| NCT05647551 | A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections | COMPLETED | PHASE4 | 2023-01-05 | 2023-10-05 | 2023-10-05 |
| NCT05691699 | A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults | COMPLETED | PHASE1 | 2023-01-03 | 2023-10-23 | 2023-10-23 |
| NCT05652205 | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | COMPLETED | PHASE3 | 2022-12-29 | 2025-09-02 | 2025-09-02 |
| NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | RECRUITING | PHASE3 | 2022-12-27 | 2029-04 | 2027-03 |
| NCT05599984 | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2022-12-05 | 2026-06 | 2026-06 |
| NCT05644977 | A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease | COMPLETED | PHASE1 | 2022-12-02 | 2025-04-14 | 2025-04-14 |
| NCT05601882 | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2022-11-28 | 2024-08-08 | 2024-03-19 |
| NCT05513703 | A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | TERMINATED | PHASE2 | 2022-11-21 | 2024-10-28 | 2024-10-28 |
| NCT05259839 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | RECRUITING | PHASE1 | 2022-10-20 | 2033-09 | 2033-09 |
| NCT05556226 | Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants | COMPLETED | PHASE1 | 2022-10-18 | 2023-02-17 | 2023-02-17 |
| NCT05456685 | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-09-28 | 2026-11 | 2026-11 |
| NCT05567029 | Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers. | COMPLETED | PHASE1 | 2022-09-28 | 2023-04-20 | 2023-04-20 |
| NCT05538585 | A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor | COMPLETED | PHASE1 | 2022-09-27 | 2022-12-21 | 2022-12-21 |
| NCT05530278 | A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis | COMPLETED | PHASE1 | 2022-09-20 | 2022-11-29 | 2022-11-29 |
| NCT05454033 | A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth | COMPLETED | PHASE3 | 2022-09-07 | 2024-09-03 | 2024-09-03 |
| NCT05443724 | A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | COMPLETED | PHASE2 | 2022-09-02 | 2025-06-25 | 2025-06-25 |
| NCT05496335 | A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines | COMPLETED | PHASE1 | 2022-08-30 | 2023-05-30 | 2023-05-30 |
| NCT05368558 | Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia | TERMINATED | PHASE3 | 2022-08-18 | 2024-09-20 | 2024-09-20 |
| NCT05291234 | A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-08-15 | 2025-11 | 2025-11 |
| NCT05475821 | Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants | TERMINATED | PHASE1 | 2022-07-25 | 2022-09-26 | 2022-09-26 |
| NCT05411198 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma | RECRUITING | PHASE3 | 2022-07-22 | 2026-01 | 2026-01 |
| NCT05414201 | A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis | COMPLETED | PHASE4 | 2022-07-07 | 2024-06-10 | 2024-06-10 |
| NCT05439616 | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | COMPLETED | PHASE3 | 2022-07-07 | 2024-10-04 | 2024-10-04 |
| NCT05376839 | A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment | TERMINATED | PHASE1 | 2022-07-06 | 2022-11-08 | 2022-11-08 |
| NCT05227690 | A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia | COMPLETED | PHASE2 | 2022-06-30 | 2024-08-26 | 2024-08-23 |
| NCT05227703 | A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia | COMPLETED | PHASE2 | 2022-06-30 | 2024-09-11 | 2024-08-15 |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-05-17 | 2025-12 | 2024-02-07 |
| NCT05316233 | A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants | COMPLETED | PHASE3 | 2022-05-02 | 2024-09-12 | 2024-09-12 |
| NCT05216250 | Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | COMPLETED | PHASE2 | 2022-04-12 | 2025-02-03 | 2025-02-03 |
| NCT05141006 | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | COMPLETED | PHASE2 | 2022-03-29 | 2024-12-06 | 2024-07-05 |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | RECRUITING | PHASE2 | 2022-03-28 | 2029-01 | 2026-11 |
| NCT04928846 | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | RECRUITING | PHASE3 | 2022-03-25 | 2028-03 | 2028-03 |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-03-24 | 2026-03 | 2026-03 |
| NCT05216263 | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | COMPLETED | PHASE3 | 2022-03-22 | 2025-05-02 | 2025-05-02 |
| NCT05248867 | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | COMPLETED | PHASE3 | 2022-03-16 | 2023-03-17 | 2023-03-17 |
| NCT05264129 | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine | COMPLETED | PHASE4 | 2022-03-07 | 2023-04-04 | 2023-04-04 |
| NCT05248893 | A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | COMPLETED | PHASE3 | 2022-02-25 | 2023-06-26 | 2023-06-26 |
| NCT05068284 | A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease | TERMINATED | PHASE2 | 2022-01-31 | 2023-07-20 | 2023-07-20 |
| NCT05094050 | Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease | COMPLETED | PHASE1 | 2022-01-18 | 2023-03-17 | 2023-03-17 |
| NCT04895410 | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma | TERMINATED | PHASE1 | 2022-01-17 | 2022-06-24 | 2022-06-24 |
| NCT05127954 | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) | ENROLLING_BY_INVITATION | PHASE3 | 2022-01-14 | 2028-01 | 2028-01 |
| NCT05125302 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | RECRUITING | PHASE3 | 2022-01-13 | 2026-05 | 2026-05 |
| NCT05407636 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | RECRUITING | PHASE3 | 2022-01-13 | 2027-11 | 2026-10 |
| NCT05144243 | Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China | ACTIVE_NOT_RECRUITING | PHASE4 | 2022-01-06 | 2026-03 | 2026-03 |
| NCT05139602 | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are NaĂŻve to Biologic Therapy | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-12-28 | 2026-01 | 2026-01 |
| NCT05134649 | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | COMPLETED | PHASE3 | 2021-11-16 | 2023-08-18 | 2023-08-18 |
| NCT05044234 | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | TERMINATED | PHASE2 | 2021-11-16 | 2022-11-30 | 2022-11-30 |
| NCT03400306 | A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | WITHDRAWN | PHASE1 | 2021-11-15 | 2021-11-16 | 2021-11-16 |
| NCT05105841 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-11-08 | 2025-11 | 2025-11 |
| NCT05028569 | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | COMPLETED | PHASE3 | 2021-11-05 | 2024-11-06 | 2024-11-06 |
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab | RECRUITING | PHASE1 | 2021-11-01 | 2027-06 | 2026-07 |
| NCT05069597 | Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon | COMPLETED | PHASE4 | 2021-10-14 | 2023-08-28 | 2023-07-07 |
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-10-13 | 2027-11 | 2027-11 |
| NCT04976777 | A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina | COMPLETED | PHASE3 | 2021-10-12 | 2022-02-09 | 2022-02-09 |
| NCT04948645 | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis | TERMINATED | PHASE1 | 2021-09-22 | 2025-07-15 | 2025-07-15 |
| NCT04853368 | Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis | TERMINATED | PHASE2 | 2021-09-20 | 2023-06-05 | 2023-06-05 |
| NCT04972968 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 | TERMINATED | PHASE2 | 2021-09-09 | 2023-07-24 | 2023-07-24 |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | COMPLETED | PHASE2 | 2021-08-31 | 2024-12-12 | 2024-01-17 |
| NCT04903626 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) | COMPLETED | PHASE3 | 2021-08-24 | 2024-09-17 | 2024-09-17 |
| NCT04965272 | A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone | WITHDRAWN | PHASE2 | 2021-08-18 | 2021-08-24 | 2021-08-24 |
| NCT04880876 | A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) | ENROLLING_BY_INVITATION | PHASE3 | 2021-08-13 | 2032-12 | 2032-12 |
| NCT04994535 | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | COMPLETED | PHASE3 | 2021-08-10 | 2023-06-14 | 2023-06-14 |
| NCT04862286 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-07-24 | 2028-04 | 2028-04 |
| NCT04949399 | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | COMPLETED | PHASE3 | 2021-07-08 | 2022-12-20 | 2022-12-20 |
| NCT04810598 | Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function | COMPLETED | PHASE1 | 2021-07-08 | 2022-08-16 | 2022-08-16 |
| NCT04927975 | Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo | COMPLETED | PHASE2 | 2021-06-30 | 2023-08-29 | 2023-01-13 |
| NCT04912063 | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | TERMINATED | PHASE1 | 2021-06-25 | 2023-05-09 | 2023-05-09 |
| NCT04888585 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | TERMINATED | PHASE2 | 2021-06-23 | 2023-08-04 | 2022-08-25 |
| NCT04958031 | A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy | COMPLETED | PHASE2 | 2021-06-22 | 2025-02-13 | 2025-02-13 |
| NCT04908475 | Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy | COMPLETED | PHASE4 | 2021-06-09 | 2023-04-20 | 2023-04-20 |
| NCT04807972 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis | TERMINATED | PHASE1 | 2021-05-28 | 2024-03-25 | 2024-03-25 |
| NCT04913610 | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection | TERMINATED | PHASE2 | 2021-05-22 | 2023-08-29 | 2023-08-29 |
| NCT04837482 | A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age | COMPLETED | PHASE3 | 2021-05-14 | 2021-12-07 | 2021-12-07 |
| NCT04777357 | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | RECRUITING | PHASE3 | 2021-04-28 | 2027-03 | 2027-03 |
| NCT04804254 | Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers | TERMINATED | PHASE1 | 2021-04-27 | 2023-01-11 | 2023-01-11 |
| NCT04554966 | Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1) | COMPLETED | PHASE1 | 2021-04-16 | 2023-08-14 | 2023-08-14 |
| NCT04480086 | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | TERMINATED | PHASE1 | 2021-03-17 | 2023-07-28 | 2023-07-28 |
| NCT04818515 | Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine | COMPLETED | PHASE1 | 2021-03-17 | 2021-06-18 | 2021-06-18 |
| NCT04799353 | Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV) | COMPLETED | PHASE1 | 2021-03-15 | 2022-10-11 | 2022-10-11 |
| NCT04777994 | Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | RECRUITING | PHASE1 | 2021-03-09 | 2026-10 | 2026-10 |
| NCT04713592 | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | COMPLETED | PHASE3 | 2021-02-26 | 2023-04-20 | 2023-04-20 |
| NCT04760769 | Open-label Trial in Parkinson's Disease (PD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-02-24 | 2026-01 | 2026-01 |
| NCT04721015 | Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-02-23 | 2026-02 | 2026-02 |
| NCT04832724 | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) | COMPLETED | PHASE2 | 2021-02-22 | 2024-03-18 | 2023-10-02 |
| NCT04686136 | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-02-19 | 2025-10-08 | 2025-10-08 |
| NCT04750226 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-02-18 | 2026-04 | 2026-04 |
| NCT04578756 | Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-02-01 | 2025-10 | 2025-10 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | RECRUITING | PHASE2, PHASE3 | 2020-12-29 | 2027-11 | 2026-12 |
| NCT04666675 | A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil | WITHDRAWN | PHASE3 | 2020-12-24 | 2021-03-23 | 2021-03-23 |
| NCT04644120 | Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19) | COMPLETED | PHASE1 | 2020-12-10 | 2021-08-24 | 2021-08-24 |
| NCT04686786 | An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | COMPLETED | PHASE2 | 2020-12-08 | 2024-12-05 | 2024-12-05 |
| NCT04567550 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-11-20 | 2026-12 | 2026-06 |
| NCT04499248 | AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension | RECRUITING | PHASE1, PHASE2 | 2020-11-16 | 2029-02 | 2029-02 |
| NCT04454658 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-11-11 | 2027-01 | 2027-01 |
| NCT04309474 | A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | COMPLETED | PHASE2 | 2020-11-09 | 2024-12-23 | 2024-04-18 |
| NCT04570631 | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma | TERMINATED | PHASE1 | 2020-11-05 | 2025-05-05 | 2025-05-05 |
| NCT04380142 | Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease | COMPLETED | PHASE3 | 2020-10-19 | 2021-09-29 | 2021-09-29 |
| NCT04509622 | A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | COMPLETED | PHASE3 | 2020-10-05 | 2021-04-15 | 2021-04-15 |
| NCT04524611 | Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-30 | 2028-02 | 2028-02 |
| NCT04472598 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | COMPLETED | PHASE3 | 2020-09-29 | 2025-01-29 | 2023-04-13 |
| NCT04542499 | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) | COMPLETED | PHASE3 | 2020-09-23 | 2024-02-15 | 2024-01-29 |
| NCT04477486 | Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | COMPLETED | PHASE2 | 2020-09-23 | 2025-05-28 | 2022-02-09 |
| NCT04064827 | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-16 | 2027-03 | 2026-11 |
| NCT05274087 | Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers | COMPLETED | PHASE1 | 2020-09-15 | 2021-04-07 | 2021-04-07 |
| NCT04401748 | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-10 | 2026-03 | 2026-03 |
| NCT04295538 | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-09-06 | 2026-01 | 2026-01 |
| NCT05274100 | Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants | COMPLETED | PHASE1 | 2020-09-01 | 2021-07-06 | 2021-07-06 |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-08-31 | 2026-12 | 2025-01-29 |
| NCT04514653 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE) | RECRUITING | PHASE2 | 2020-08-25 | 2026-08-01 | 2025-10-21 |
| NCT04492020 | Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants | COMPLETED | PHASE3 | 2020-08-21 | 2022-04-19 | 2022-04-19 |
| NCT04333576 | Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | RECRUITING | PHASE3 | 2020-08-10 | 2030-06 | 2029-03 |
| NCT04451772 | A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State | COMPLETED | PHASE2 | 2020-07-27 | 2024-01-03 | 2024-01-03 |
| NCT04403763 | Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia | TERMINATED | PHASE1, PHASE2 | 2020-07-27 | 2022-12-05 | 2022-12-05 |
| NCT04451720 | Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis | COMPLETED | PHASE3 | 2020-07-20 | 2022-11-21 | 2022-11-21 |
| NCT04435600 | A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms | COMPLETED | PHASE3 | 2020-07-14 | 2024-10-15 | 2024-02-12 |
| NCT04430855 | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | COMPLETED | PHASE2 | 2020-07-14 | 2022-01-25 | 2021-04-22 |
| NCT04274907 | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | TERMINATED | PHASE1 | 2020-06-30 | 2021-02-02 | 2021-02-02 |
| NCT04382885 | Cariprazine Pediatric ASD PK Study | COMPLETED | PHASE1 | 2020-06-26 | 2021-12-10 | 2021-12-10 |
| NCT04437433 | A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | COMPLETED | PHASE3 | 2020-06-18 | 2024-06-11 | 2024-06-11 |
| NCT04285580 | A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension | COMPLETED | PHASE3 | 2020-06-11 | 2022-05-14 | 2022-05-14 |
| NCT04379050 | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-06-08 | 2026-04 | 2026-04 |
| NCT04375397 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | COMPLETED | PHASE2 | 2020-06-06 | 2021-06-08 | 2021-05-10 |
| NCT04417465 | First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors | COMPLETED | PHASE1 | 2020-06-03 | 2025-08-21 | 2025-08-21 |
| NCT04254783 | A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease | COMPLETED | PHASE1 | 2020-05-27 | 2022-10-14 | 2022-10-14 |
| NCT04274933 | A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy | TERMINATED | PHASE1 | 2020-05-21 | 2020-10-08 | 2020-10-08 |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma | TERMINATED | PHASE1 | 2020-05-19 | 2021-04-16 | 2021-04-16 |
| NCT04274894 | A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism | COMPLETED | PHASE4 | 2020-05-12 | 2022-01-07 | 2021-12-07 |
| NCT04315311 | Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer | WITHDRAWN | PHASE4 | 2020-05-06 | 2021-09-22 | 2021-09-22 |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | TERMINATED | PHASE1 | 2020-05-05 | 2022-06-27 | 2022-06-27 |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-03-26 | 2026-06 | 2022-09-29 |
| NCT05217472 | An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS) | WITHDRAWN | PHASE2 | 2020-03-06 | 2022-05-15 | 2022-04-15 |
| NCT04030962 | A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease | COMPLETED | PHASE1, PHASE2 | 2020-03-04 | 2022-03-18 | 2022-03-18 |
| NCT04127695 | A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease | WITHDRAWN | PHASE1 | 2020-03-03 | 2020-06-16 | 2020-06-16 |
| NCT04161885 | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | TERMINATED | PHASE3 | 2020-02-26 | 2025-09-23 | 2025-09-23 |
| NCT03859869 | A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI) | TERMINATED | PHASE4 | 2020-02-25 | 2022-03-23 | 2022-03-23 |
| NCT04262791 | A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD) | TERMINATED | PHASE1 | 2020-02-17 | 2022-01-31 | 2022-01-31 |
| NCT04189614 | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-02-13 | 2025-12 | 2025-12 |
| NCT04161898 | A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-02-04 | 2027-08 | 2027-08 |
| NCT04223804 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 | COMPLETED | PHASE1 | 2020-01-30 | 2023-02-27 | 2023-02-27 |
| NCT04244175 | A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | COMPLETED | PHASE2 | 2020-01-27 | 2024-05-21 | 2024-05-21 |
| NCT04196283 | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | COMPLETED | PHASE1 | 2020-01-22 | 2022-10-27 | 2022-10-27 |
| NCT03818542 | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma | TERMINATED | PHASE1 | 2020-01-22 | 2020-09-23 | 2020-09-23 |
| NCT04195698 | Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2020-01-15 | 2023-09-11 | 2023-09-11 |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | COMPLETED | PHASE2 | 2020-01-14 | 2021-11-04 | 2021-11-04 |
| NCT04223193 | Flexible-Dose Trial in Early Parkinson's Disease (PD) | COMPLETED | PHASE3 | 2020-01-06 | 2024-10-01 | 2024-10-01 |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression | COMPLETED | PHASE3 | 2019-12-31 | 2024-10-29 | 2023-03-06 |
| NCT04201093 | Fixed-Dose Trial in Early Parkinson's Disease (PD) | COMPLETED | PHASE3 | 2019-12-13 | 2024-06-28 | 2024-06-28 |
| NCT03969888 | A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 | COMPLETED | PHASE2 | 2019-12-11 | 2022-06-09 | 2022-06-09 |
| NCT04169373 | A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis | COMPLETED | PHASE3 | 2019-11-26 | 2025-02-21 | 2021-09-02 |
| NCT04166058 | Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C | COMPLETED | PHASE3 | 2019-11-19 | 2025-06-05 | 2025-06-05 |
| NCT04102007 | A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab | COMPLETED | PHASE3 | 2019-11-12 | 2022-11-07 | 2022-01-17 |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-11-08 | 2026-12-31 | 2026-12-31 |
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-11-06 | 2027-02 | 2027-02 |
| NCT03924947 | A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis | COMPLETED | PHASE4 | 2019-10-23 | 2022-07-11 | 2022-07-11 |
| NCT04026113 | Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) | COMPLETED | PHASE3 | 2019-10-01 | 2024-05-29 | 2024-05-20 |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-09-06 | 2026-02 | 2026-02 |
| NCT04073303 | BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence | COMPLETED | PHASE3 | 2019-08-29 | 2022-11-10 | 2022-11-10 |
| NCT03941964 | A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | COMPLETED | PHASE3 | 2019-08-15 | 2022-03-14 | 2022-03-14 |
| NCT03951077 | Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome | COMPLETED | PHASE2 | 2019-08-12 | 2021-02-10 | 2021-02-10 |
| NCT03557619 | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies | RECRUITING | PHASE1 | 2019-07-30 | 2026-03-21 | 2026-03-21 |
| NCT03978520 | A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE2 | 2019-07-25 | 2022-07-14 | 2022-01-19 |
| NCT05268068 | A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China | COMPLETED | PHASE1 | 2019-06-27 | 2020-04-26 | 2020-04-26 |
| NCT03725007 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-06-24 | 2027-05 | 2027-05 |
| NCT03922607 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis | COMPLETED | PHASE1 | 2019-06-11 | 2021-04-13 | 2021-04-13 |
| NCT03875508 | A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE3 | 2019-06-04 | 2020-08-25 | 2020-04-24 |
| NCT03926169 | A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2019-06-03 | 2021-08-02 | 2021-02-02 |
| NCT03999801 | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | ENROLLING_BY_INVITATION | PHASE2 | 2019-05-31 | 2028-12 | 2028-12 |
| NCT03924323 | A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | COMPLETED | PHASE4 | 2019-05-30 | 2021-09-20 | 2021-09-20 |
| NCT03893955 | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-05-21 | 2026-03 | 2026-03 |
| NCT03823378 | A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib | TERMINATED | PHASE2 | 2019-05-13 | 2020-09-09 | 2020-09-09 |
| NCT03875482 | A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE3 | 2019-05-13 | 2020-07-15 | 2020-02-20 |
| NCT03781167 | A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) | COMPLETED | PHASE3 | 2019-04-29 | 2022-08-17 | 2022-08-17 |
| NCT03785184 | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | WITHDRAWN | PHASE2 | 2019-04-29 | 2019-08-22 | 2019-08-22 |
| NCT03886220 | A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | COMPLETED | PHASE4 | 2019-04-12 | 2021-04-28 | 2021-03-31 |
| NCT05283681 | A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants | COMPLETED | PHASE1 | 2019-04-02 | 2019-11-11 | 2019-11-11 |
| NCT03891446 | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-03-27 | 2026-08 | 2026-07 |
| NCT03823391 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA) | COMPLETED | PHASE2 | 2019-03-27 | 2020-08-26 | 2020-04-08 |
| NCT03695185 | A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | COMPLETED | PHASE2 | 2019-03-26 | 2022-01-10 | 2021-04-05 |
| NCT03675308 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-03-25 | 2026-09-28 | 2020-10-08 |
| NCT03712787 | An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) | TERMINATED | PHASE2 | 2019-03-22 | 2021-09-30 | 2021-09-30 |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | TERMINATED | PHASE1 | 2019-03-18 | 2019-12-30 | 2019-12-30 |
| NCT05486195 | A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect | COMPLETED | PHASE1 | 2019-03-14 | 2020-03-11 | 2019-07-29 |
| NCT03671148 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-03-07 | 2026-06 | 2020-06-22 |
| NCT03779841 | Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA) | COMPLETED | PHASE2 | 2019-03-01 | 2023-03-06 | 2022-03-24 |
| NCT03850782 | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | COMPLETED | PHASE3 | 2019-02-28 | 2025-08-08 | 2025-08-08 |
| NCT03737812 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis | COMPLETED | PHASE2 | 2019-02-27 | 2021-08-30 | 2021-01-15 |
| NCT03821935 | Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-02-21 | 2027-06 | 2027-06 |
| NCT03738397 | A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2019-02-21 | 2020-12-09 | 2020-08-27 |
| NCT03725202 | A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis | COMPLETED | PHASE3 | 2019-02-06 | 2025-02-24 | 2024-02-06 |
| NCT03646604 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis | COMPLETED | PHASE1 | 2019-01-31 | 2024-08-29 | 2024-08-29 |
| NCT03706040 | A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2018-12-27 | 2021-04-26 | 2020-10-28 |
| NCT03737851 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis | COMPLETED | PHASE2 | 2018-12-11 | 2021-09-09 | 2021-08-09 |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE3 | 2018-12-06 | 2021-01-14 | 2021-01-14 |
| NCT03739203 | The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone | COMPLETED | PHASE3 | 2018-11-10 | 2021-09-06 | 2021-09-06 |
| NCT03738215 | Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone | COMPLETED | PHASE3 | 2018-11-09 | 2021-09-30 | 2021-09-30 |
| NCT03661138 | A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE3 | 2018-10-27 | 2022-08-19 | 2022-08-19 |
| NCT03695237 | A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) | COMPLETED | PHASE3 | 2018-10-24 | 2023-11-29 | 2021-05-06 |
| NCT03639194 | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | COMPLETED | PHASE1 | 2018-10-24 | 2024-01-25 | 2024-01-25 |
| NCT03539744 | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-10-22 | 2027-11 | 2026-08 |
| NCT03625505 | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | COMPLETED | PHASE1 | 2018-10-18 | 2021-08-31 | 2021-08-31 |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | TERMINATED | PHASE2 | 2018-10-18 | 2020-06-18 | 2020-06-18 |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-10-10 | 2026-08 | 2025-10 |
| NCT03682705 | A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2018-10-08 | 2020-03-26 | 2020-03-26 |
| NCT03543358 | A Long-Term Study of Rovalpituzumab Tesirine | COMPLETED | PHASE2 | 2018-09-10 | 2019-11-26 | 2019-11-26 |
| NCT03398135 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-08-28 | 2029-02 | 2029-02 |
| NCT03569293 | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-08-13 | 2025-09-09 | 2021-01-06 |
| NCT03406156 | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | COMPLETED | PHASE3 | 2018-08-10 | 2023-07-12 | 2021-10-12 |
| NCT03568318 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | ENROLLING_BY_INVITATION | PHASE3 | 2018-08-09 | 2030-10-23 | 2021-02-16 |
| NCT03219437 | A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE3 | 2018-07-30 | 2021-11-26 | 2021-11-26 |
| NCT03593213 | Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia | TERMINATED | PHASE3 | 2018-07-30 | 2021-02-11 | 2021-02-11 |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | TERMINATED | PHASE3 | 2018-07-30 | 2020-03-03 | 2019-09-05 |
| NCT03607422 | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-07-27 | 2025-11-04 | 2021-03-11 |
| NCT03484520 | A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | TERMINATED | PHASE1 | 2018-07-23 | 2022-12-01 | 2022-12-01 |
| NCT03518047 | Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation | COMPLETED | PHASE3 | 2018-07-19 | 2020-02-11 | 2020-02-11 |
| NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2018-07-13 | 2025-06 | 2025-06 |
| NCT03573297 | A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features | COMPLETED | PHASE3 | 2018-06-15 | 2022-09-05 | 2022-09-05 |
| NCT03219216 | A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection | COMPLETED | PHASE3 | 2018-06-06 | 2019-03-11 | 2019-03-11 |
| NCT03441555 | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | COMPLETED | PHASE1 | 2018-05-30 | 2021-01-25 | 2021-01-25 |
| NCT03478787 | Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE3 | 2018-05-08 | 2020-07-08 | 2020-07-08 |
| NCT03518034 | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | COMPLETED | PHASE4 | 2018-05-03 | 2023-01-19 | 2023-01-19 |
| NCT03374917 | A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment | COMPLETED | PHASE1 | 2018-04-18 | 2019-03-04 | 2019-03-04 |
| NCT03413319 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | COMPLETED | PHASE1 | 2018-04-17 | 2019-11-20 | 2019-11-20 |
| NCT03105102 | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-04-09 | 2026-05 | 2026-05 |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-04-02 | 2031-05 | 2031-05 |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-03-21 | 2027-09 | 2027-09 |
| NCT03368859 | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab | TERMINATED | PHASE2 | 2018-03-20 | 2019-12-18 | 2019-12-18 |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | TERMINATED | PHASE1 | 2018-03-16 | 2020-12-19 | 2020-12-19 |
| NCT03334487 | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | WITHDRAWN | PHASE3 | 2018-03-15 | 2018-12-20 | 2018-12-20 |
| NCT03398148 | A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE2, PHASE3 | 2018-03-07 | 2023-05-11 | 2022-11-09 |
| NCT03391765 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | TERMINATED | PHASE2 | 2018-01-24 | 2019-12-13 | 2019-12-13 |
| NCT03316794 | A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | TERMINATED | PHASE1 | 2018-01-04 | 2018-10-05 | 2018-10-05 |
| NCT02955212 | A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) | COMPLETED | PHASE3 | 2018-01-03 | 2020-09-03 | 2019-08-14 |
| NCT03386513 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2018-01-02 | 2026-12-30 | 2023-09-06 |
| NCT03343067 | A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain | TERMINATED | PHASE3 | 2017-12-27 | 2018-10-23 | 2018-10-23 |
| NCT03104413 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment | COMPLETED | PHASE3 | 2017-12-18 | 2021-05-19 | 2020-11-30 |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | COMPLETED | PHASE3 | 2017-12-07 | 2022-01-13 | 2021-10-15 |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | COMPLETED | PHASE3 | 2017-11-29 | 2021-08-11 | 2021-08-11 |
| NCT03181126 | A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma | COMPLETED | PHASE1 | 2017-11-27 | 2020-11-14 | 2020-11-11 |
| NCT03339128 | Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children | RECRUITING | PHASE2 | 2017-11-15 | 2026-12 | 2026-12 |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | COMPLETED | PHASE1 | 2017-11-08 | 2023-04-19 | 2023-04-19 |
| NCT03311477 | A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors | COMPLETED | PHASE1 | 2017-11-06 | 2019-03-04 | 2019-03-04 |
| NCT03222609 | A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis | COMPLETED | PHASE2 | 2017-10-31 | 2025-01-29 | 2022-03-28 |
| NCT03311464 | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan | COMPLETED | PHASE3 | 2017-10-27 | 2020-04-21 | 2019-08-20 |
| NCT03178487 | A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis | COMPLETED | PHASE2 | 2017-10-24 | 2022-02-17 | 2019-01-21 |
| NCT05305222 | A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab | COMPLETED | PHASE1 | 2017-10-23 | 2018-06-15 | 2018-06-15 |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | RECRUITING | PHASE2 | 2017-10-12 | 2029-05 | 2029-05 |
| NCT03234712 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) | COMPLETED | PHASE1 | 2017-10-10 | 2021-04-14 | 2021-04-14 |
| NCT03222583 | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection | COMPLETED | PHASE3 | 2017-10-04 | 2019-02-15 | 2018-10-18 |
| NCT03235349 | Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection | COMPLETED | PHASE3 | 2017-09-29 | 2019-02-25 | 2018-11-15 |
| NCT03271489 | Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | COMPLETED | PHASE3 | 2017-09-13 | 2024-06-28 | 2024-06-28 |
| NCT03253185 | A Study of SC-007 in Subjects With Advanced Cancer | TERMINATED | PHASE1 | 2017-09-13 | 2018-04-02 | 2018-03-20 |
| NCT05283694 | A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants | COMPLETED | PHASE1 | 2017-09-11 | 2018-06-12 | 2018-06-12 |
| NCT02951117 | A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | WITHDRAWN | PHASE1 | 2017-08-31 | 2021-04-28 | 2020-07-28 |
| NCT03255382 | A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy | COMPLETED | PHASE3 | 2017-08-22 | 2018-07-06 | 2018-07-06 |
| NCT03212521 | Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 | COMPLETED | PHASE3 | 2017-08-07 | 2018-08-13 | 2018-08-13 |
| NCT03213457 | A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain | COMPLETED | PHASE3 | 2017-07-07 | 2023-12-06 | 2020-03-27 |
| NCT03145909 | A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) | TERMINATED | PHASE1 | 2017-07-03 | 2018-11-27 | 2018-11-27 |
| NCT03138408 | SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers | TERMINATED | PHASE1 | 2017-06-14 | 2019-05-02 | 2019-05-02 |
| NCT03069352 | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | COMPLETED | PHASE3 | 2017-05-23 | 2025-08-21 | 2019-02-15 |
| NCT03033498 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease | COMPLETED | PHASE1 | 2017-05-17 | 2019-06-08 | 2019-06-08 |
| NCT03148756 | Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis | TERMINATED | PHASE2 | 2017-05-12 | 2017-08-04 | 2017-08-04 |
| NCT03105128 | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 | 2017-05-10 | 2021-04-14 | 2020-11-09 |
| NCT03086343 | A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs | COMPLETED | PHASE3 | 2017-05-09 | 2023-06-06 | 2019-06-13 |
| NCT03145948 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis | TERMINATED | PHASE1 | 2017-05-09 | 2017-08-16 | 2017-08-16 |
| NCT03104374 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug | COMPLETED | PHASE3 | 2017-05-01 | 2024-09-30 | 2019-07-23 |
| NCT03086239 | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer | COMPLETED | PHASE1 | 2017-04-28 | 2018-08-20 | 2018-01-30 |
| NCT03089944 | A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis | COMPLETED | PHASE3 | 2017-04-28 | 2019-11-08 | 2019-07-31 |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | COMPLETED | PHASE3 | 2017-04-27 | 2024-09-09 | 2019-09-26 |
| NCT03061812 | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) | COMPLETED | PHASE3 | 2017-04-11 | 2020-02-12 | 2020-02-12 |
| NCT02814916 | Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA | COMPLETED | PHASE3 | 2017-03-30 | 2024-01-01 | 2024-01-01 |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | TERMINATED | PHASE1, PHASE2 | 2017-03-30 | 2019-07-03 | 2019-07-03 |
| NCT03069365 | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment | COMPLETED | PHASE3 | 2017-03-28 | 2018-06-05 | 2018-02-20 |
| NCT03071757 | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1 | 2017-03-21 | 2022-04-13 | 2022-04-13 |
| NCT03067129 | A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2, PHASE3 | 2017-03-20 | 2022-09-12 | 2020-05-21 |
| NCT03082209 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | COMPLETED | PHASE1 | 2017-03-20 | 2022-01-21 | 2022-01-21 |
| NCT03035279 | A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | TERMINATED | PHASE1 | 2017-03-08 | 2019-03-28 | 2019-03-28 |
| NCT02966782 | A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) | COMPLETED | PHASE1 | 2017-03-07 | 2023-04-05 | 2023-04-05 |
| NCT03047395 | A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) | COMPLETED | PHASE3 | 2017-02-27 | 2023-11-29 | 2023-11-29 |
| NCT02988960 | A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2017-02-22 | 2026-03 | 2026-03 |
| NCT02799381 | A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) | COMPLETED | PHASE3 | 2017-02-09 | 2019-09-19 | 2019-09-19 |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) | TERMINATED | PHASE3 | 2017-02-07 | 2019-11-20 | 2019-11-20 |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment NaĂŻve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2017-02-02 | 2026-01-23 | 2021-12-01 |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | ACTIVE_NOT_RECRUITING | PHASE3 | 2017-01-31 | 2027-07 | 2027-07 |
| NCT02880956 | A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease | COMPLETED | PHASE2 | 2017-01-26 | 2021-07-28 | 2021-03-30 |
| NCT03022045 | A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | COMPLETED | PHASE3 | 2017-01-26 | 2020-11-19 | 2017-09-17 |
| NCT02966795 | A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection | COMPLETED | PHASE3 | 2017-01-25 | 2018-08-29 | 2018-06-06 |
| NCT02899052 | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | ACTIVE_NOT_RECRUITING | PHASE2 | 2017-01-19 | 2027-06 | 2027-06 |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-NaĂŻve Higher-Risk Myelodysplastic Syndromes (MDS) | ACTIVE_NOT_RECRUITING | PHASE1 | 2017-01-12 | 2027-01 | 2027-01 |
| NCT02944396 | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE1 | 2016-12-23 | 2019-10-02 | 2019-10-02 |
| NCT02986373 | A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) | COMPLETED | PHASE2 | 2016-12-15 | 2018-07-30 | 2018-07-08 |
| NCT03000257 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-12-14 | 2022-03-29 | 2022-03-29 |
| NCT02980731 | A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). | COMPLETED | PHASE3 | 2016-12-13 | 2021-12-29 | 2021-12-29 |
| NCT02985879 | A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) | TERMINATED | PHASE2 | 2016-12-12 | 2019-11-20 | 2019-11-20 |
| NCT03000075 | BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE2 | 2016-12-02 | 2018-06-20 | 2017-09-21 |
| NCT02939989 | Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study | COMPLETED | PHASE3 | 2016-11-21 | 2021-07-30 | 2021-05-07 |
| NCT02955251 | A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-11-18 | 2019-10-29 | 2019-10-29 |
| NCT02968173 | A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus | COMPLETED | PHASE3 | 2016-11-09 | 2017-07-13 | 2017-07-13 |
| NCT02925117 | A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis | COMPLETED | PHASE2 | 2016-10-25 | 2019-01-31 | 2017-08-10 |
| NCT02601885 | A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis | COMPLETED | PHASE1 | 2016-10-18 | 2018-04-20 | 2018-04-20 |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer | TERMINATED | PHASE1 | 2016-10 | 2019-05-31 | 2019-05-31 |
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | COMPLETED | PHASE2, PHASE3 | 2016-09-26 | 2021-12-13 | 2021-12-13 |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2016-09-23 | 2019-08-27 | 2019-08-27 |
| NCT02772601 | This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis | COMPLETED | PHASE1 | 2016-09-15 | 2017-09-22 | 2017-06-15 |
| NCT02925494 | An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | COMPLETED | PHASE3 | 2016-09-14 | 2019-03-22 | 2018-05-07 |
| NCT02897115 | A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment | TERMINATED | PHASE4 | 2016-09-12 | 2017-12-21 | 2017-12-21 |
| NCT02904902 | Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa | COMPLETED | PHASE3 | 2016-09-06 | 2019-05-30 | 2017-09-01 |
| NCT02806362 | Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) | WITHDRAWN | PHASE3 | 2016-09 | 2018-08 | 2018-06 |
| NCT02814175 | A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) | COMPLETED | PHASE4 | 2016-08-05 | 2020-03-19 | 2019-09-23 |
| NCT02808975 | Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically | COMPLETED | PHASE4 | 2016-07-18 | 2019-10-16 | 2019-05-16 |
| NCT02755597 | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | COMPLETED | PHASE3 | 2016-07-11 | 2022-08-15 | 2021-03-15 |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | WITHDRAWN | PHASE1 | 2016-07 | 2021-02 | 2020-01 |
| NCT02756611 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE3 | 2016-06-22 | 2022-03-11 | 2019-04-10 |
| NCT02782663 | A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease | COMPLETED | PHASE2 | 2016-05-18 | 2025-07-18 | 2025-07-18 |
| NCT02738138 | A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) | COMPLETED | PHASE3 | 2016-05-17 | 2017-06-07 | 2017-03-15 |
| NCT02692703 | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) | COMPLETED | PHASE3 | 2016-04-22 | 2017-06-29 | 2017-04-13 |
| NCT02723084 | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection | COMPLETED | PHASE3 | 2016-04-08 | 2017-03-24 | 2017-01-19 |
| NCT02688790 | Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection | TERMINATED | PHASE1 | 2016-04-01 | 2019-04-03 | 2019-04-03 |
| NCT02719171 | BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis | COMPLETED | PHASE2 | 2016-04 | 2017-08 | 2017-05 |
| NCT02706951 | A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) | COMPLETED | PHASE3 | 2016-03-23 | 2022-08-10 | 2017-10-02 |
| NCT02720523 | A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs | COMPLETED | PHASE2, PHASE3 | 2016-03-22 | 2022-06-07 | 2017-08-03 |
| NCT02706847 | A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs | COMPLETED | PHASE3 | 2016-03-15 | 2022-02-08 | 2017-04-03 |
| NCT02684357 | BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2016-03 | 2017-09 | 2016-12 |
| NCT02694523 | BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2016-03 | 2017-08 | 2017-08 |
| NCT02672852 | BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment | COMPLETED | PHASE3 | 2016-02-29 | 2018-07-26 | 2017-08-02 |
| NCT02706873 | A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate | COMPLETED | PHASE3 | 2016-02-23 | 2022-11-10 | 2018-03-15 |
| NCT02707952 | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE3 | 2016-02-22 | 2017-02-09 | 2016-11-14 |
| NCT02691494 | Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study) | COMPLETED | PHASE3 | 2016-02-03 | 2019-01-23 | 2018-02-14 |
| NCT02684370 | BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2016-02 | 2017-09 | 2016-12 |
| NCT02674568 | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer | COMPLETED | PHASE2 | 2016-01-25 | 2018-10-19 | 2018-10-19 |
| NCT02654054 | Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women | COMPLETED | PHASE3 | 2015-12-22 | 2018-12-12 | 2018-01-18 |
| NCT02675426 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone | COMPLETED | PHASE3 | 2015-12-17 | 2022-03-10 | 2017-04-21 |
| NCT02556736 | RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa | COMPLETED | PHASE1, PHASE2 | 2015-12-14 | 2024-10-21 | 2020-06-01 |
| NCT02642432 | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis | COMPLETED | PHASE3 | 2015-12-07 | 2017-02-10 | 2016-10-27 |
| NCT02629159 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | ACTIVE_NOT_RECRUITING | PHASE3 | 2015-12-01 | 2027-09-30 | 2017-10-27 |
| NCT02640157 | A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection | COMPLETED | PHASE3 | 2015-12 | 2017-02 | 2016-10 |
| NCT02573740 | Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment | TERMINATED | PHASE1 | 2015-12 | 2016-06 | 2016-06 |
| NCT02651194 | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection | COMPLETED | PHASE3 | 2015-12 | 2017-01 | 2016-10 |
| NCT02632175 | Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis | COMPLETED | PHASE3 | 2015-11-26 | 2025-04-08 | 2025-04-08 |
| NCT02582632 | A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-NaĂŻve Hepatitis C Virus Genotype 1b-Infected Adults | COMPLETED | PHASE3 | 2015-11-24 | 2016-12-01 | 2016-08-24 |
| NCT02636595 | The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) | COMPLETED | PHASE3 | 2015-11 | 2017-01 | 2016-10 |
| NCT02640482 | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection | COMPLETED | PHASE3 | 2015-11 | 2017-02 | 2016-09 |
| NCT02598570 | Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | COMPLETED | PHASE1 | 2015-11 | 2017-02 | 2016-12 |
| NCT02486406 | A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects | COMPLETED | PHASE2, PHASE3 | 2015-10-28 | 2020-11-19 | 2020-11-19 |
| NCT02609659 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection | COMPLETED | PHASE3 | 2015-10-28 | 2016-12-28 | 2016-10-07 |
| NCT02549092 | A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) | COMPLETED | PHASE3 | 2015-10-26 | 2022-11-18 | 2020-05-14 |
| NCT02604017 | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection | COMPLETED | PHASE3 | 2015-10 | 2017-01 | 2017-01 |
| NCT02606630 | [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis | TERMINATED | PHASE1 | 2015-10 | 2015-12 | 2015-12 |
| NCT02429895 | A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 | TERMINATED | PHASE2 | 2015-10 | 2016-05 | 2016-05 |
| NCT02487199 | Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease | COMPLETED | PHASE3 | 2015-09-30 | 2016-12-05 | 2016-12-05 |
| NCT02533375 | Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | COMPLETED | PHASE3 | 2015-09-28 | 2017-07-20 | 2016-09-15 |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2015-09-18 | 2019-03-25 | 2019-03-25 |
| NCT02513459 | A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE2 | 2015-09-16 | 2019-06-19 | 2019-06-19 |
| NCT02534870 | Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects | COMPLETED | PHASE1 | 2015-09 | 2015-09 | 2015-09 |
| NCT02507687 | Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension | COMPLETED | PHASE3 | 2015-08-27 | 2023-05-31 | 2021-11-24 |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | COMPLETED | PHASE1, PHASE2 | 2015-08-24 | 2020-08-27 | 2020-08-27 |
| NCT02499783 | Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease | COMPLETED | PHASE3 | 2015-08-17 | 2017-12-15 | 2017-05-19 |
| NCT02596217 | Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers | COMPLETED | PHASE1 | 2015-08 | 2017-06 | 2017-06 |
| NCT02517528 | ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment NaĂŻve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis | COMPLETED | PHASE3 | 2015-07-20 | 2017-03-16 | 2016-09-29 |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | TERMINATED | PHASE3 | 2015-07-14 | 2023-10-05 | 2019-05-03 |
| NCT02504099 | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma | TERMINATED | PHASE3 | 2015-07 | 2016-12 | 2016-09 |
| NCT02517515 | ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-NaĂŻve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2015-07 | 2017-06 | 2016-10 |
| NCT02483104 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | COMPLETED | PHASE1 | 2015-07 | 2016-07 | 2016-03 |
| NCT02531178 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2015-07 | 2016-02 | 2016-02 |
| NCT02443298 | Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma | COMPLETED | PHASE2 | 2015-06-23 | 2018-02-02 | 2017-10-13 |
| NCT02441283 | A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 | COMPLETED | PHASE2, PHASE3 | 2015-06-22 | 2019-10-15 | 2019-10-15 |
| NCT02493855 | Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults | COMPLETED | PHASE2 | 2015-06 | 2016-12 | 2016-04 |
| NCT02476617 | Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults | COMPLETED | PHASE3 | 2015-06 | 2016-12 | 2016-08 |
| NCT02442284 | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection | COMPLETED | PHASE3 | 2015-05-13 | 2016-10-31 | 2016-08-22 |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | TERMINATED | PHASE1 | 2015-05-06 | 2017-12-06 | 2017-12-06 |
| NCT02412371 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | TERMINATED | PHASE1, PHASE2 | 2015-04-30 | 2019-08-05 | 2019-08-05 |
| NCT02349451 | A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) | COMPLETED | PHASE2 | 2015-04-28 | 2016-07-04 | 2016-07-04 |
| NCT02442271 | A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil | COMPLETED | PHASE3 | 2015-04-27 | 2016-09-26 | 2016-07-04 |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | COMPLETED | PHASE1 | 2015-04-14 | 2019-07-05 | 2019-07-05 |
| NCT02118714 | Atrasentan Spermatogenesis and Testicular Function | COMPLETED | PHASE2 | 2015-04-06 | 2018-07-16 | 2018-04-18 |
| NCT02446717 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy | COMPLETED | PHASE2, PHASE3 | 2015-04 | 2017-01 | 2016-12 |
| NCT02433340 | Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study | COMPLETED | PHASE2 | 2015-04 | 2016-05 | 2016-05 |
| NCT02365649 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy | COMPLETED | PHASE2 | 2015-03-17 | 2017-08-03 | 2016-11-25 |
| NCT02384538 | A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis | COMPLETED | PHASE2 | 2015-03 | 2016-07 | 2016-07 |
| NCT02399345 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults | COMPLETED | PHASE3 | 2015-03 | 2015-11 | 2015-11 |
| NCT02442258 | Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function | COMPLETED | PHASE1 | 2015-03 | 2015-12 | 2015-12 |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | COMPLETED | PHASE2 | 2015-02-17 | 2019-06-24 | 2019-06-24 |
| NCT02356562 | A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE2 | 2015-02-03 | 2017-07-07 | 2016-10-28 |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | TERMINATED | PHASE1 | 2015-01-09 | 2018-03-15 | 2018-03-15 |
| NCT02198651 | A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects | COMPLETED | PHASE4 | 2015-01-05 | 2018-08-08 | 2018-05-03 |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification | COMPLETED | PHASE3 | 2015-01-04 | 2022-04-04 | 2022-04-04 |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-NaĂŻve Participants With Acute Myelogenous Leukemia | COMPLETED | PHASE1, PHASE2 | 2014-12-31 | 2021-08-10 | 2021-08-10 |
| NCT02292719 | A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE2 | 2014-12-19 | 2017-07-14 | 2017-07-14 |
| NCT02305758 | Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | COMPLETED | PHASE2 | 2014-12-02 | 2017-09-22 | 2017-09-22 |
| NCT02219477 | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis | COMPLETED | PHASE3 | 2014-11-24 | 2017-03-03 | 2016-06-13 |
| NCT02203851 | Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE2 | 2014-11-20 | 2018-09-04 | 2018-09-04 |
| NCT02247401 | Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt | COMPLETED | PHASE3 | 2014-11-04 | 2016-08-01 | 2016-08-01 |
| NCT02219490 | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2014-10-30 | 2021-05-13 | 2021-05-13 |
| NCT02265237 | A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) | COMPLETED | PHASE3 | 2014-10-28 | 2017-04-07 | 2016-07-28 |
| NCT02065557 | Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis | COMPLETED | PHASE3 | 2014-10-13 | 2020-02-07 | 2020-02-07 |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | COMPLETED | PHASE1, PHASE2 | 2014-10-13 | 2019-04-17 | 2019-04-17 |
| NCT02203773 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | TERMINATED | PHASE1 | 2014-10-06 | 2022-06-16 | 2022-06-16 |
| NCT02296905 | Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function | COMPLETED | PHASE1 | 2014-10 | 2015-09 | 2015-09 |
| NCT02264990 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | COMPLETED | PHASE3 | 2014-09-30 | 2020-02-21 | 2019-11-14 |
| NCT02207088 | Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease | COMPLETED | PHASE3 | 2014-09-23 | 2016-12-06 | 2016-12-06 |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | COMPLETED | PHASE1, PHASE2 | 2014-09-22 | 2021-03-12 | 2021-03-12 |
| NCT02243293 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection | COMPLETED | PHASE2, PHASE3 | 2014-09-19 | 2017-02-23 | 2016-10-25 |
| NCT02141282 | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy | COMPLETED | PHASE2 | 2014-09-10 | 2021-12-22 | 2021-12-22 |
| NCT02220738 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | TERMINATED | PHASE1 | 2014-09 | 2016-03 | 2016-03 |
| NCT02219503 | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis | COMPLETED | PHASE3 | 2014-09 | 2015-09 | 2015-06 |
| NCT02216422 | A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection | COMPLETED | PHASE3 | 2014-09 | 2015-12 | 2015-12 |
| NCT02095574 | A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma | WITHDRAWN | PHASE1 | 2014-09 | 2015-01 | 2014-09 |
| NCT02185014 | Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115 | COMPLETED | PHASE3 | 2014-08-12 | 2017-11-03 | 2017-11-03 |
| NCT02196701 | Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | COMPLETED | PHASE3 | 2014-08-05 | 2017-03-17 | 2017-03-17 |
| NCT02243280 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection | COMPLETED | PHASE2 | 2014-08 | 2016-02 | 2016-02 |
| NCT02141997 | A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate | COMPLETED | PHASE2 | 2014-07 | 2015-11 | 2015-09 |
| NCT02210663 | A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2014-07 | 2016-07 | 2016-01 |
| NCT02167945 | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2014-06-12 | 2021-05-13 | 2021-05-13 |
| NCT02087904 | A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis | COMPLETED | PHASE2 | 2014-06-04 | 2016-12-13 | 2016-06-07 |
| NCT02148718 | Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease | COMPLETED | PHASE4 | 2014-06 | 2017-01 | 2016-08 |
| NCT02143713 | Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain | COMPLETED | PHASE3 | 2014-05-27 | 2017-05-23 | 2016-06-22 |
| NCT02065570 | Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease | COMPLETED | PHASE3 | 2014-05-01 | 2020-01-30 | 2020-01-30 |
| NCT02106546 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | COMPLETED | PHASE3 | 2014-04-10 | 2019-11-20 | 2017-01-03 |
| NCT02163694 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | COMPLETED | PHASE3 | 2014-04-08 | 2024-01-25 | 2019-04-05 |
| NCT02032277 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | COMPLETED | PHASE3 | 2014-04-02 | 2020-11-12 | 2016-03-18 |
| NCT02068222 | A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection | COMPLETED | PHASE2 | 2014-04 | 2015-03 | 2015-03 |
| NCT01969682 | A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 | WITHDRAWN | PHASE1 | 2014-04 | 2014-05 | 2014-05 |
| NCT02065622 | Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis | COMPLETED | PHASE3 | 2014-03-27 | 2019-11-11 | 2019-09-05 |
| NCT02066389 | A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone | COMPLETED | PHASE2 | 2014-03-26 | 2015-07-02 | 2015-07-02 |
| NCT02082249 | An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications | COMPLETED | PHASE3 | 2014-03-10 | 2019-10-31 | 2019-10-31 |
| NCT02082197 | An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men | WITHDRAWN | PHASE3 | 2014-03 | 2015-06 | 2015-06 |
| NCT02031276 | Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease. | COMPLETED | PHASE2 | 2014-02 | 2016-11 | 2015-12 |
| NCT02047110 | BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS) | COMPLETED | PHASE2 | 2014-01-28 | 2016-07-25 | 2015-03-05 |
| NCT02049138 | An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis | COMPLETED | PHASE2 | 2014-01-24 | 2021-07-29 | 2021-07-29 |
| NCT02099058 | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2014-01-15 | 2026-08 | 2026-08 |
| NCT02023112 | Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2014-01 | 2015-09 | 2015-04 |
| NCT02016482 | A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis | COMPLETED | PHASE3 | 2014-01 | 2016-04 | 2015-10 |
| NCT02052362 | Bioavailability of ABT-450 and ABT-267 With Ritonavir | COMPLETED | PHASE1 | 2014-01 | 2014-02 | 2014-02 |
| NCT01969695 | An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2013-12-20 | 2019-12-16 | 2019-12-16 |
| NCT02033551 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2013-12 | 2016-09 | 2016-09 |
| NCT02023099 | Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2013-12 | 2015-10 | 2014-10 |
| NCT02015793 | Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease | COMPLETED | PHASE2 | 2013-12 | 2015-02 | 2015-02 |
| NCT01969669 | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 | COMPLETED | PHASE1 | 2013-12 | 2014-09 | 2014-09 |
| NCT01995071 | A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) | COMPLETED | PHASE2 | 2013-11 | 2015-06 | 2015-06 |
| NCT01994837 | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) | COMPLETED | PHASE2 | 2013-11 | 2014-12 | 2014-12 |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | COMPLETED | PHASE1 | 2013-11 | 2014-12 | 2014-12 |
| NCT02052349 | Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects | COMPLETED | PHASE1 | 2013-11 | 2013-12 | 2013-12 |
| NCT01960855 | A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy | COMPLETED | PHASE2 | 2013-10 | 2015-07 | 2015-07 |
| NCT01960842 | A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications | COMPLETED | PHASE3 | 2013-10 | 2015-03 | 2015-03 |
| NCT01931670 | A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain | COMPLETED | PHASE3 | 2013-09-09 | 2016-12-19 | 2016-01-06 |
| NCT01958827 | A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease | COMPLETED | PHASE3 | 2013-09 | 2015-10 | 2015-03 |
| NCT01939197 | A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection | COMPLETED | PHASE2, PHASE3 | 2013-08-30 | 2016-10-25 | 2016-07-21 |
| NCT01933919 | A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder | COMPLETED | PHASE3 | 2013-08-14 | 2016-07-01 | 2015-06-18 |
| NCT01946074 | A Study of ABT-165 in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2013-08-08 | 2022-09-28 | 2022-09-28 |
| NCT01853033 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2013-07 | 2014-05 | 2014-05 |
| NCT01908010 | Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | COMPLETED | PHASE1 | 2013-07 | 2013-11 | 2013-11 |
| NCT01889186 | A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion | COMPLETED | PHASE2 | 2013-06-27 | 2020-12-15 | 2020-10-28 |
| NCT01773070 | A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study | COMPLETED | PHASE3 | 2013-06 | 2016-10 | 2016-10 |
| NCT01854528 | A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults | COMPLETED | PHASE3 | 2013-06 | 2015-07 | 2014-11 |
| NCT01858532 | Study Of Diabetic Nephropathy With Atrasentan | TERMINATED | PHASE3 | 2013-05-17 | 2018-03-29 | 2018-03-29 |
| NCT01897519 | A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery | TERMINATED | PHASE2 | 2013-05 | 2014-05 | 2014-05 |
| NCT01808118 | Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis | COMPLETED | PHASE3 | 2013-04-16 | 2017-04-14 | 2017-02-21 |
| NCT01817530 | Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) | COMPLETED | PHASE2 | 2013-04-08 | 2015-12 | 2015-06 |
| NCT01800695 | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme | COMPLETED | PHASE1 | 2013-04-02 | 2017-06-19 | 2017-06-19 |
| NCT01911845 | An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine | COMPLETED | PHASE2 | 2013-04 | 2014-09 | 2013-12 |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2013-03-18 | 2017-06-29 | 2017-05-03 |
| NCT01736176 | A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease | COMPLETED | PHASE3 | 2013-03 | 2015-12 | 2015-03 |
| NCT01833533 | A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection | COMPLETED | PHASE3 | 2013-03 | 2014-09 | 2013-12 |
| NCT01854697 | A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before | COMPLETED | PHASE3 | 2013-03 | 2015-07 | 2014-11 |
| NCT01834638 | Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) | TERMINATED | PHASE2 | 2013-03 | 2014-11 | 2014-11 |
| NCT01782495 | A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients | COMPLETED | PHASE2 | 2013-02-25 | 2017-07-13 | 2016-11-02 |
| NCT01777165 | A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery | COMPLETED | PHASE2 | 2013-02 | 2014-03 | 2014-03 |
| NCT01760954 | Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain | COMPLETED | PHASE3 | 2012-12-28 | 2016-04-15 | 2015-05 |
| NCT01609933 | A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study | COMPLETED | PHASE2 | 2012-12-18 | 2017-05-03 | 2017-05-03 |
| NCT01767116 | A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection | COMPLETED | PHASE3 | 2012-12 | 2014-08 | 2013-12 |
| NCT01752855 | Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab | COMPLETED | PHASE2 | 2012-12 | 2013-10 | 2013-10 |
| NCT01794507 | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | COMPLETED | PHASE1 | 2012-11-19 | 2019-07-16 | 2019-07-16 |
| NCT01716585 | A Study to Evaluate Chronic Hepatitis C Infection | COMPLETED | PHASE3 | 2012-11 | 2014-10 | 2013-10 |
| NCT01715415 | A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults | COMPLETED | PHASE3 | 2012-11 | 2014-10 | 2013-11 |
| NCT01686555 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) | COMPLETED | PHASE1 | 2012-11 | 2015-06 | 2015-06 |
| NCT01741493 | A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 | COMPLETED | PHASE1 | 2012-11 | 2013-12 | 2013-12 |
| NCT01657799 | Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer | COMPLETED | PHASE2 | 2012-10-19 | 2015-01-22 | 2015-01-22 |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE1, PHASE2 | 2012-10-10 | 2021-11-29 | 2021-11-29 |
| NCT01704755 | A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis | COMPLETED | PHASE3 | 2012-10 | 2014-09 | 2014-01 |
| NCT01741727 | A Study of ABT-414 in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2012-10 | 2015-11 | 2015-11 |
| NCT01690195 | Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease | TERMINATED | PHASE2 | 2012-09 | 2014-02 | 2014-02 |
| NCT01668511 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee | COMPLETED | PHASE1 | 2012-09 | 2013-10 | 2013-10 |
| NCT01678755 | A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia | COMPLETED | PHASE2 | 2012-08 | 2014-03 | 2014-03 |
| NCT01685203 | A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE2 | 2012-08 | 2015-02 | 2014-06 |
| NCT01674725 | A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C | COMPLETED | PHASE3 | 2012-08 | 2014-10 | 2014-01 |
| NCT01676935 | This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease | TERMINATED | PHASE2 | 2012-08 | 2014-03 | 2014-03 |
| NCT01646073 | Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis | COMPLETED | PHASE3 | 2012-08 | 2013-12 | 2013-12 |
| NCT01682616 | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | COMPLETED | PHASE1 | 2012-07-25 | 2022-06-23 | 2022-06-23 |
| NCT01672983 | A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE2 | 2012-07 | 2014-05 | 2014-05 |
| NCT01589419 | A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | COMPLETED | PHASE1 | 2012-06 | 2015-01 | 2015-01 |
| NCT01557777 | Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE2 | 2012-06 | 2013-07 | 2013-07 |
| NCT01712178 | A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety | COMPLETED | PHASE2 | 2012-06 | 2013-05 | 2013-05 |
| NCT01620528 | A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain | COMPLETED | PHASE3 | 2012-05-22 | 2015-09-28 | 2014-11-14 |
| NCT01594229 | A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | COMPLETED | PHASE1 | 2012-05-21 | 2020-07-14 | 2020-07-14 |
| NCT01506947 | A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients | COMPLETED | PHASE4 | 2012-05-10 | 2016-04-07 | 2016-04-07 |
| NCT01655680 | A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia | COMPLETED | PHASE2 | 2012-05 | 2014-07 | 2014-04 |
| NCT01550965 | A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting | COMPLETED | PHASE3 | 2012-05 | 2015-04 | 2015-04 |
| NCT01644396 | An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation | COMPLETED | PHASE4 | 2012-05 | 2013-09 | 2013-09 |
| NCT01617928 | A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | COMPLETED | PHASE1 | 2012-05 | 2013-07 | 2013-07 |
| NCT01635764 | Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa | COMPLETED | PHASE3 | 2012-04 | 2016-08 | 2016-08 |
| NCT01577550 | Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis | COMPLETED | PHASE1 | 2012-04 | 2014-05 | 2013-10 |
| NCT01579279 | A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain | TERMINATED | PHASE2 | 2012-04 | 2012-05 | 2012-05 |
| NCT01589432 | A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy | COMPLETED | PHASE2 | 2012-04 | 2012-11 | 2012-11 |
| NCT01549834 | Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | COMPLETED | PHASE2 | 2012-03 | 2013-10 | 2013-10 |
| NCT01561313 | Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. | COMPLETED | PHASE2 | 2012-03 | 2012-11 | 2012-11 |
| NCT01560104 | A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | COMPLETED | PHASE2 | 2012-02 | 2014-09 | 2014-09 |
| NCT01563536 | Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects | COMPLETED | PHASE2 | 2012-02 | 2013-06 | 2012-04 |
| NCT01527916 | Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2012-02 | 2013-11 | 2013-11 |
| NCT01506609 | Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | COMPLETED | PHASE2 | 2012-01-23 | 2020-09-02 | 2018-12-13 |
| NCT01502423 | A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab | COMPLETED | PHASE2 | 2012-01 | 2012-11 | 2012-11 |
| NCT01741142 | Efficacy and Safety Study of ABT-436 in Major Depressive Disorder | TERMINATED | PHASE2 | 2012-01 | 2015-08 | 2013-10 |
| NCT01468207 | Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa | COMPLETED | PHASE3 | 2011-11 | 2014-01 | 2014-01 |
| NCT01468233 | Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa | COMPLETED | PHASE3 | 2011-11 | 2014-04 | 2014-04 |
| NCT01472016 | Study of ABT-700 in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2011-10-06 | 2017-04-27 | 2017-04-27 |
| NCT01406119 | An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2011-10 | 2017-01 | 2017-01 |
| NCT01382212 | A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis | COMPLETED | PHASE3 | 2011-10 | 2015-04 | 2015-04 |
| NCT01479127 | Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease | COMPLETED | PHASE2 | 2011-10 | 2012-07 | 2012-07 |
| NCT01464827 | ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients | COMPLETED | PHASE2 | 2011-10 | 2013-09 | 2013-03 |
| NCT01444365 | A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee | COMPLETED | PHASE2 | 2011-10 | 2012-04 | 2012-04 |
| NCT01472003 | An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types | COMPLETED | PHASE1 | 2011-10 | 2012-12 | 2012-12 |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | COMPLETED | PHASE2 | 2011-09-08 | 2014-05-17 | 2013-11 |
| NCT01458535 | A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-NaĂŻve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) | COMPLETED | PHASE2 | 2011-09 | 2013-05 | 2013-05 |
| NCT01424319 | Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan | COMPLETED | PHASE2 | 2011-08 | 2012-07 | 2012-07 |
| NCT01399580 | A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy | COMPLETED | PHASE2 | 2011-08 | 2012-09 | 2012-09 |
| NCT01466062 | Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions | COMPLETED | PHASE3 | 2011-08 | 2012-04 | 2012-04 |
| NCT01364922 | Phase 2 Chronic Low Back Pain Study | COMPLETED | PHASE2 | 2011-06 | 2011-10 | 2011-10 |
| NCT01403038 | An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females | COMPLETED | PHASE1 | 2011-06 | 2012-11 | 2012-10 |
| NCT01413893 | An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1 | 2011-06 | 2012-06 | 2012-06 |
| NCT01380704 | Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder | COMPLETED | PHASE1 | 2011-06 | 2011-09 | 2011-09 |
| NCT01328626 | A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma | COMPLETED | PHASE1 | 2011-05-23 | 2020-05-08 | 2020-05-08 |
| NCT01192568 | Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder | COMPLETED | PHASE4 | 2011-05-17 | 2023-10-24 | 2023-08-29 |
| NCT01339650 | Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | COMPLETED | PHASE1 | 2011-05-06 | 2017-11-30 | 2017-11-30 |
| NCT01341782 | Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism | COMPLETED | PHASE3 | 2011-05 | 2012-04 | 2012-04 |
| NCT01333722 | Acute Pain Study Following Bunionectomy | COMPLETED | PHASE2 | 2011-04 | 2011-06 | 2011-06 |
| NCT01356849 | Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor | COMPLETED | PHASE2 | 2011-04 | 2012-08 | 2012-08 |
| NCT01345045 | A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain | COMPLETED | PHASE2 | 2011-04 | 2011-10 | 2011-10 |
| NCT01314261 | Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects | COMPLETED | PHASE2 | 2011-03 | 2013-02 | 2012-01 |
| NCT01235689 | Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease | COMPLETED | PHASE3 | 2011-02-11 | 2017-01-03 | 2016-11-03 |
| NCT01306617 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-NaĂŻve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2011-02 | 2012-10 | 2011-11 |
| NCT01251614 | A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate | COMPLETED | PHASE3 | 2010-12 | 2015-02 | 2013-12 |
| NCT01148225 | A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis | COMPLETED | PHASE3 | 2010-11-23 | 2018-05-21 | 2018-05-21 |
| NCT01255657 | A Study of ABT-806 in Subjects With Advanced Solid Tumor Types | COMPLETED | PHASE1 | 2010-11 | 2012-11 | 2012-11 |
| NCT01221298 | A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) | COMPLETED | PHASE2 | 2010-10 | 2012-04 | 2011-05 |
| NCT01243671 | A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease | COMPLETED | PHASE3 | 2010-10 | 2013-06 | 2012-03 |
| NCT01185301 | Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) | COMPLETED | PHASE3 | 2010-10 | 2012-09 | 2012-09 |
| NCT01265823 | Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE4 | 2010-10 | 2012-02 | 2012-02 |
| NCT01166282 | A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis | COMPLETED | PHASE3 | 2010-09 | 2015-12 | 2012-11 |
| NCT01162421 | A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis | COMPLETED | PHASE4 | 2010-09 | 2015-07 | 2015-07 |
| NCT01185288 | A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA) | COMPLETED | PHASE4 | 2010-09 | 2013-01 | 2013-01 |
| NCT01207115 | A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee | COMPLETED | PHASE2 | 2010-09 | 2011-05 | 2011-05 |
| NCT01225302 | A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE1 | 2010-09 | 2012-06 | 2012-06 |
| NCT01138657 | Efficacy and Safety of Adalimumab in Patients With Active Uveitis | COMPLETED | PHASE3 | 2010-08 | 2014-08 | 2014-07 |
| NCT01124838 | Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis | COMPLETED | PHASE3 | 2010-08 | 2015-05 | 2015-05 |
| NCT01199224 | To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2010-06 | 2010-11 | 2010-11 |
| NCT01163617 | The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients | COMPLETED | PHASE2 | 2010-05 | 2010-11 | 2010-11 |
| NCT01137526 | Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2010-05 | 2011-07 | 2011-07 |
| NCT01133548 | Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males | COMPLETED | PHASE1 | 2010-05 | 2010-07 | 2010-07 |
| NCT01130298 | An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier | COMPLETED | PHASE1 | 2010-05 | 2010-05 | 2010-05 |
| NCT01121133 | A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax | COMPLETED | PHASE1 | 2010-05 | 2011-05 | 2011-05 |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | COMPLETED | PHASE1 | 2010-04 | 2013-06 | 2013-06 |
| NCT01085422 | A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer | COMPLETED | PHASE1 | 2010-04 | 2011-06 | 2011-06 |
| NCT01484990 | A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease | COMPLETED | PHASE1 | 2010-04 | 2010-09 | 2010-09 |
| NCT01123876 | Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor | COMPLETED | PHASE1 | 2010-03 | 2015-01 | 2015-01 |
| NCT01074008 | A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 | COMPLETED | PHASE2 | 2010-03 | 2012-01 | 2011-06 |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | COMPLETED | PHASE2 | 2010-03 | 2013-06 | 2013-06 |
| NCT01110486 | ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors | COMPLETED | PHASE1 | 2010-03 | 2013-09 | 2013-09 |
| NCT01095562 | Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia | COMPLETED | PHASE2 | 2010-03 | 2011-09 | 2011-08 |
| NCT01077700 | Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia | COMPLETED | PHASE2 | 2010-03 | 2011-07 | 2011-07 |
| NCT01064856 | Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) | COMPLETED | PHASE3 | 2010-02 | 2014-05 | 2011-08 |
| NCT01020487 | Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) | COMPLETED | PHASE3 | 2010-02 | 2014-12 | 2014-05 |
| NCT01063816 | A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2010-01 | 2016-08 | 2016-08 |
| NCT00660387 | Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | COMPLETED | PHASE3 | 2009-12 | 2011-10 | 2011-10 |
| NCT01038609 | Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy | COMPLETED | PHASE2 | 2009-12 | 2010-05 | 2010-05 |
| NCT01018875 | Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2009-12 | 2011-02 | 2011-02 |
| NCT00660673 | Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease | COMPLETED | PHASE3 | 2009-11-13 | 2021-11-30 | 2021-11-30 |
| NCT00868413 | Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | COMPLETED | PHASE1 | 2009-11 | 2013-05 | 2013-05 |
| NCT00973973 | Efficacy and Safety Study of Elagolix in Women With Endometriosis | COMPLETED | PHASE2 | 2009-10-12 | 2010-09-22 | 2010-09-22 |
| NCT01009073 | A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects | COMPLETED | PHASE1 | 2009-10 | 2013-06 | 2013-06 |
| NCT00948909 | Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2009-10 | 2010-11 | 2010-11 |
| NCT00878449 | A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer | COMPLETED | PHASE1 | 2009-10 | 2011-07 | 2011-07 |
| NCT00986037 | Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma | COMPLETED | PHASE1 | 2009-10 | | 2010-07 |
| NCT00982566 | Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer | COMPLETED | PHASE1 | 2009-10 | 2010-12 | 2010-10 |
| NCT00887757 | Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2009-09 | 2011-11 | 2011-11 |
| NCT00788684 | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | COMPLETED | PHASE1 | 2009-07-21 | 2025-02-07 | 2025-02-07 |
| NCT00939003 | Study of Adalimumab in Patients With Axial Spondyloarthritis | COMPLETED | PHASE3 | 2009-07 | 2013-08 | 2011-02 |
| NCT00891605 | Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2009-07 | 2012-07 | 2012-07 |
| NCT00360568 | Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects | COMPLETED | PHASE3 | 2009-06 | 2012-10 | 2012-10 |
| NCT00935311 | Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction | COMPLETED | PHASE2 | 2009-06 | 2009-08 | 2009-08 |
| NCT00920764 | A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors | COMPLETED | PHASE2 | 2009-06 | 2010-05 | 2010-04 |
| NCT00872196 | A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies | COMPLETED | PHASE2 | 2009-04 | 2010-04 | 2010-04 |
| NCT00775437 | Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use | COMPLETED | PHASE3 | 2009-03 | 2013-03 | 2013-03 |
| NCT00851890 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2009-03 | 2009-07 | 2009-07 |
| NCT00804908 | A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma | COMPLETED | PHASE2 | 2009-02 | 2016-01 | 2016-01 |
| NCT00853099 | A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE3 | 2009-02 | 2013-08 | 2011-05 |
| NCT00733187 | Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 | COMPLETED | PHASE1 | 2009-02 | 2012-06 | 2012-06 |
| NCT00850044 | Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1 | COMPLETED | PHASE1 | 2009-02 | | 2009-07 |
| NCT00357994 | Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | COMPLETED | PHASE3 | 2009-01 | 2011-10 | 2011-10 |
| NCT00808509 | A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission | COMPLETED | PHASE4 | 2009-01 | 2012-09 | 2012-09 |
| NCT00667446 | Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty | COMPLETED | PHASE3 | 2008-12 | 2013-01 | 2012-10 |
| NCT00797225 | Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis | COMPLETED | PHASE2 | 2008-11-26 | 2010-02-24 | 2010-02-24 |
| NCT00888693 | A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia | COMPLETED | PHASE1 | 2008-11 | | 2009-12 |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | COMPLETED | PHASE2 | 2008-10 | 2012-05 | 2012-05 |
| NCT00761150 | Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) | COMPLETED | PHASE3 | 2008-09 | 2009-03 | 2009-03 |
| NCT00763321 | Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) | COMPLETED | PHASE3 | 2008-09 | 2009-04 | 2009-04 |
| NCT00718380 | A Phase 1 Study of ABT-869 in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2008-09 | 2012-06 | 2012-06 |
| NCT00742560 | A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma | COMPLETED | PHASE2 | 2008-08 | 2016-10 | 2016-10 |
| NCT00726882 | A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies | COMPLETED | PHASE2 | 2008-08 | 2010-05 | 2010-05 |
| NCT00710580 | Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2008-07 | 2009-04 | 2009-04 |
| NCT00645177 | Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer | COMPLETED | PHASE2 | 2008-07 | 2009-12 | 2009-12 |
| NCT00716534 | Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE2 | 2008-06 | 2012-04 | 2012-04 |
| NCT00696904 | Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects | COMPLETED | PHASE1 | 2008-06 | | 2009-02 |
| NCT00686374 | Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 | COMPLETED | PHASE3 | 2008-05-01 | 2017-04-04 | 2017-04-04 |
| NCT00691964 | Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2008-05 | 2009-03 | 2009-03 |
| NCT00686933 | Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2008-05 | 2008-10 | 2008-10 |
| NCT00679731 | A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE3 | 2008-04 | 2009-11 | 2009-11 |
| NCT00649207 | A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases | COMPLETED | PHASE1 | 2008-03 | 2013-03 | 2013-03 |
| NCT00640419 | Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2008-03 | 2008-07 | 2008-07 |
| NCT00640185 | Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2008-03 | 2008-08 | 2008-08 |
| NCT00619866 | An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis | COMPLETED | PHASE2 | 2008-02-19 | 2009-08-28 | 2009-04-20 |
| NCT00616772 | Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood | COMPLETED | PHASE3 | 2008-02 | 2012-09 | 2012-09 |
| NCT00497146 | The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 | COMPLETED | PHASE3 | 2008-02 | 2012-03 | 2010-09 |
| NCT00626002 | Open Label Continuation Study in Moderate to Severe Psoriasis | COMPLETED | PHASE3 | 2008-02 | 2011-10 | 2011-10 |
| NCT00335153 | Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease | COMPLETED | PHASE3 | 2008-01 | 2012-06 | 2012-06 |
| NCT00654758 | A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE1 | 2007-12 | 2010-05 | 2010-05 |
| NCT00573794 | Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis | COMPLETED | PHASE3 | 2007-11-28 | 2016-12 | 2016-12 |
| NCT00570986 | A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2007-11 | 2009-06 | 2009-06 |
| NCT00548925 | A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain | COMPLETED | PHASE2 | 2007-11 | 2008-12 | 2008-12 |
| NCT00517920 | Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) | COMPLETED | PHASE2 | 2007-09 | 2012-06 | 2011-06 |
| NCT00528697 | A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2007-09 | 2008-04 | 2008-04 |
| NCT00507936 | Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain | COMPLETED | PHASE2 | 2007-08 | 2008-10 | 2008-10 |
| NCT00517790 | Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE2 | 2007-08 | 2012-06 | 2011-06 |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | COMPLETED | PHASE1 | 2007-08 | | 2010-06 |
| NCT00481091 | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | COMPLETED | PHASE1, PHASE2 | 2007-07-25 | 2022-05-12 | 2022-05-12 |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | COMPLETED | PHASE1, PHASE2 | 2007-07 | 2009-10 | 2008-10 |
| NCT00486538 | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | COMPLETED | PHASE2 | 2007-06 | 2012-06 | 2011-06 |
| NCT00650156 | Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis | COMPLETED | PHASE1 | 2007-06 | | 2007-10 |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | COMPLETED | PHASE1, PHASE2 | 2007-04 | 2010-12 | 2010-12 |
| NCT00443391 | A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) | COMPLETED | PHASE2 | 2007-02 | 2008-10 | 2008-10 |
| NCT00437658 | Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis | COMPLETED | PHASE2 | 2006-12-11 | 2008-11-24 | 2008-11-24 |
| NCT00406809 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | COMPLETED | PHASE1, PHASE2 | 2006-11 | 2016-10 | 2016-10 |
| NCT00297089 | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | COMPLETED | PHASE1, PHASE2 | 2006-11 | 2009-01 | 2009-01 |
| NCT00141518 | Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact | COMPLETED | PHASE4 | 2006-03 | 2011-04 | 2011-03 |
| NCT00292396 | Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE2 | 2005-11 | 2008-04 | 2008-04 |
| NCT00401570 | A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer | COMPLETED | PHASE2 | 2005-03 | 2008-06 | 2008-06 |
| NCT00086671 | Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) | COMPLETED | PHASE2 | 2004-04 | 2006-11 | 2006-11 |
| NCT00648999 | Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients | COMPLETED | PHASE4 | 2003-11 | 2006-12 | 2006-12 |
| NCT00234975 | Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score | COMPLETED | PHASE4 | 2002-10 | 2008-01 | 2008-01 |
| NCT00195663 | Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis | COMPLETED | PHASE3 | 2000-12 | 2012-04 | 2004-04 |